Holen Sie sich die Stockscreener-App
73.02
0.30%
-0.22
Handel nachbörslich:
72.71
-0.31
-0.42%
Schlusskurs vom Vortag:
$73.24
Offen:
$73.07
24-Stunden-Volumen:
941.73K
Relative Volume:
0.87
Marktkapitalisierung:
$9.40B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-15.87
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
-2.39%
1M Leistung:
-12.91%
6M Leistung:
-37.05%
1J Leistung:
-0.31%
1-Tages-Spanne:
$71.69
$76.51
1-Wochen-Bereich:
$67.23
$76.51
52-Wochen-Spanne:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Vergleichen Sie PCVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
73.02 | 9.40B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Smartleaf Asset Management LLC - Defense World
US Bancorp DE Has $408,000 Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Learn to Evaluate (PCVX) using the Charts - Stock Traders Daily
Vaxcyte’s SVP Mikhail Eydelman sells shares worth $353,699 By Investing.com - Investing.com Australia
Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares - GuruFocus.com
Mutual of America Capital Management LLC Lowers Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Bank of New York Mellon Corp Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Vaxcyte’s SVP Mikhail Eydelman sells shares worth $353,699 - Investing.com
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Truist Financial Corp - Defense World
Vaxcyte COO Jim Wassil sells $586,165 in stock By Investing.com - Investing.com Australia
Vaxcyte COO Jim Wassil sells $586,165 in stock - Investing.com India
Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Vaxcyte phase II PCV valve to open shortly, Pfizer sizers alert - BioWorld Online
Mizuho maintains Vaxcyte stock Outperform rating, $163 target - Investing.com India
Sanctuary Advisors LLC Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
(PCVX) Trading Report - Stock Traders Daily
Research Analysts Offer Predictions for Vaxcyte Q1 Earnings - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Handelsbanken Fonder AB - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by New York State Common Retirement Fund - Defense World
Q1 Earnings Estimate for Vaxcyte Issued By Leerink Partnrs - Defense World
Guggenheim Reiterates "Buy" Rating for Vaxcyte (NASDAQ:PCVX) - MarketBeat
Vaxcyte (NASDAQ:PCVX) Releases Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Vaxcyte's (PCVX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
Vaxcyte’s Promising Prospects and Strategic Engagements Justify Buy Rating - TipRanks
Vaxcyte’s Earnings Call Highlights Strong Position and Future Growth - TipRanks
Vaxcyte cites manufacturing investments at Lonza facility in Visp as key 2024 expenditure - BioProcess Insider
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus.com
Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds - Insider Monkey
Buy Rating for Vaxcyte Driven by Anticipated Positive Phase 2 Data and Undervalued Stock Potential - TipRanks
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Fina - GuruFocus.com
Vaxcyte Advances Vaccine Pipeline with Strong Financial Backing - TipRanks
Vaxcyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Vaxcyte Q4 2024 sees stock dip after earnings - Investing.com
10 Best Vaccine Stocks to Buy According to Hedge Funds - Insider Monkey
Vaxcyte 2024 Loss Narrows -February 25, 2025 at 05:22 pm EST - Marketscreener.com
Vaxcyte, Inc. SEC 10-K Report - TradingView
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts - Insider Monkey
What's Driving the Market Sentiment Around Vaxcyte? - Benzinga
Vaxcyte’s Promising Growth in the PCV Market: Analyst Recommends Buy Rating - TipRanks
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
BTIG maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com Canada
Vaxcyte’s Promising Vaccine Developments and Strong Buy Rating Backed by Robust Clinical Trials and DCF Valuation - TipRanks
15 Stocks That Will Go to The Moon According to Analysts - Insider Monkey
Rhumbline Advisers Buys 7,711 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Vaxcyte (PCVX) Expected to Announce Earnings on Tuesday - Defense World
Vaxcyte (PCVX) to Release Earnings on Tuesday - Armenian Reporter
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):